Orthofix International N.V. provided earnings guidance for the fourth quarter and full year ended December 31, 2012. For the quarter, the company anticipates net sales to be approximately $112 million. The Company expects fourth quarter 2012 adjusted earnings from continuing operations per share to be between $0.78 and $0.83. Despite the strong revenue increase in U.S. Spine Repair Implants and Regenerative Biologics business and an increase in U.S. Orthopedic Repair business, the fourth quarter revenue was negatively impacted in international markets by regulatory and macroeconomic conditions.

For the year, the company anticipates net sales from continuing operations to be approximately $462 million. The negative impact from foreign currency translation is expected to be approximately $10 million for the full year 2012. Adjusted earnings from continuing operations per share are expected to be between $3.01 and $3.06. The Company's Spine Regenerative Stimulation business was negatively impacted in the second half of the year by sales force turnover as the company initially implemented Corporate Integrity Agreement in June 2012.